CG
CLVS

Carmignac Gestion’s Clovis Oncology, Inc. CLVS Stock Holding History

Carmignac Gestion’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,514,940
Closed -$44.5M – 91
2018
Q3 		$44.5M Sell
1,514,940
-6,500
-0.4% -$252K 0.38% 44
2018
Q2 		$69.2M Buy
1,521,440
+11,900
+0.8% +$579K 0.52% 45
2018
Q1 		$79.7M Buy
1,509,540
+188,676
+14% +$11M 0.56% 44
2017
Q4 		$89.8M Buy
+1,320,864
New +$92.3M 0.6% 40

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Carmignac Gestion's CLVS Position: Q4 2018 in Review

Carmignac Gestion sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 1,514,940 shares — an estimated $44.5M sold.

Carmignac Gestion first reported a position in CLVS in Q4 2017 and held it in 4 quarters. The position peaked at $89.8M in Q4 2017. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Carmignac Gestion reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Carmignac Gestion sold 1,514,940 Clovis Oncology, Inc. shares in Q4 2018, an estimated $44.5M.
  • Carmignac Gestion first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 4 quarters.
  • Carmignac Gestion's Clovis Oncology, Inc. position peaked at $89.8M in Q4 2017.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Carmignac Gestion's 13F filing for Q4 2018, filed 13 Feb 2019.